ZBTB48
gene geneOn this page
Also known as ZNF855TZAP
Summary
ZBTB48 (zinc finger and BTB domain containing 48, HGNC:4930) is a protein-coding gene on chromosome 1p36.31, encoding Zinc finger and BTB domain-containing protein 48 (P10074). Plays a critical role in transcriptional regulation and chromatin remodeling.
Enables double-stranded telomeric DNA binding activity; identical protein binding activity; and transcription cis-regulatory region binding activity. Involved in positive regulation of DNA-templated transcription and telomere maintenance via telomere lengthening. Located in chromosome, telomeric region.
Source: NCBI Gene 3104 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 88 total
- Druggable target: yes
- Cancer driver (intOGen): activating (oncogene-like) across 1 cancer types
- MANE Select transcript:
NM_005341
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:4930 |
| Approved symbol | ZBTB48 |
| Name | zinc finger and BTB domain containing 48 |
| Location | 1p36.31 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | ZNF855, TZAP |
| Ensembl gene | ENSG00000204859 |
| Ensembl biotype | protein_coding |
| OMIM | 165270 |
| Entrez | 3104 |
Gene structure
Transcript identifiers
Ensembl transcripts: 21 — 17 protein_coding, 3 retained_intron, 1 nonsense_mediated_decay
ENST00000319084, ENST00000377674, ENST00000435905, ENST00000466813, ENST00000466941, ENST00000482360, ENST00000488936, ENST00000498342, ENST00000902993, ENST00000902994, ENST00000902995, ENST00000902996, ENST00000902997, ENST00000902998, ENST00000902999, ENST00000915764, ENST00000915765, ENST00000915766, ENST00000915767, ENST00000953434, ENST00000953435
RefSeq mRNA: 3 — MANE Select: NM_005341
NM_001278647, NM_001278648, NM_005341
CCDS: CCDS84
Canonical transcript exons
ENST00000377674 — 11 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001474830 | 6580541 | 6581299 |
| ENSE00001474832 | 6579994 | 6580136 |
| ENSE00002763933 | 6585919 | 6586030 |
| ENSE00002765041 | 6586695 | 6586787 |
| ENSE00003505740 | 6588060 | 6588196 |
| ENSE00003560397 | 6588278 | 6588442 |
| ENSE00003588406 | 6587205 | 6587291 |
| ENSE00003624634 | 6588756 | 6588844 |
| ENSE00003652787 | 6587478 | 6587632 |
| ENSE00003687096 | 6588916 | 6589280 |
| ENSE00003785133 | 6582058 | 6582299 |
Expression profiles
Bgee: expression breadth ubiquitous, 205 present calls, max score 93.77.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.0570 / max 108.5483, expressed in 1787 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 403 | 9.2103 | 1780 |
| 404 | 0.8467 | 419 |
Top tissues by expression
271 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right lobe of liver | UBERON:0001114 | 93.77 | gold quality |
| left testis | UBERON:0004533 | 93.54 | gold quality |
| granulocyte | CL:0000094 | 93.48 | gold quality |
| right testis | UBERON:0004534 | 93.47 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 92.73 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 92.25 | gold quality |
| adenohypophysis | UBERON:0002196 | 92.10 | gold quality |
| right ovary | UBERON:0002118 | 91.45 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 91.25 | gold quality |
| testis | UBERON:0000473 | 91.23 | gold quality |
| spleen | UBERON:0002106 | 91.08 | gold quality |
| left ovary | UBERON:0002119 | 90.97 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 90.61 | gold quality |
| right uterine tube | UBERON:0001302 | 90.34 | gold quality |
| pituitary gland | UBERON:0000007 | 90.19 | gold quality |
| thyroid gland | UBERON:0002046 | 89.96 | gold quality |
| ectocervix | UBERON:0012249 | 89.91 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 89.74 | gold quality |
| metanephros cortex | UBERON:0010533 | 89.73 | gold quality |
| monocyte | CL:0000576 | 89.72 | gold quality |
| endocervix | UBERON:0000458 | 89.68 | gold quality |
| tibial nerve | UBERON:0001323 | 89.68 | gold quality |
| transverse colon | UBERON:0001157 | 89.11 | gold quality |
| body of uterus | UBERON:0009853 | 89.10 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 89.08 | gold quality |
| mononuclear cell | CL:0000842 | 89.06 | gold quality |
| skin of abdomen | UBERON:0001416 | 89.04 | gold quality |
| leukocyte | CL:0000738 | 88.85 | gold quality |
| left uterine tube | UBERON:0001303 | 88.78 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 88.76 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 2.89 |
Regulation
Is transcription factor: yes
Downstream targets (CollecTRI)
1 targets.
| Target | Regulation |
|---|---|
| CDKN2A | Unknown |
JASPAR motifs
| Motif | Name | Family |
|---|---|---|
| MA2470.1 | ZBTB48 | More than 3 adjacent zinc fingers |
JASPAR matrix evidence (PMIDs): PMID:28082411
Literature-anchored findings (GeneRIF, showing 8)
- HKR3 potently activated the transcription of the tumor suppressor gene ARF by acting on the proximal promoter region (bp, -149 approximately +53), which contains Sp1 and FBI-1 binding elements (FREs). (PMID:24382891)
- this study describes a specific telomere-associated protein: TZAP (telomeric zinc finger-associated protein). Binding of TZAP to long telomeres represents the switch that triggers telomere trimming, setting the upper limit of telomere length. (PMID:28082411)
- study demonstrate through a combination of RNAseq, ChIPseq and expression proteomics experiments that ZBTB48 acts as a transcriptional activator on a small set of target genes, including mitochondrial fission process 1 (MTFP1). This discovery places ZBTB48 at the interface of telomere length regulation, transcriptional control and mitochondrial metabolism (PMID:28500257)
- The ZBTB48 (TZAP) mutation (c.1272 G > A, L424L) was found in 7.8% of128 breast cancer (BC) patients and was associated with the N0 stage. BCs with the TZAP mutation had longer telomeres than those without this mutation. Survival analysis showed that the TZAP mutation resulted in poorer overall survival. (PMID:31752241)
- Clinical and Prognostic Significance of TZAP Expression in Cervical Cancer. (PMID:32344888)
- Prognostic Value of Telomeric Zinc Finger-Associated Protein Expression in Adenocarcinoma and Squamous Cell Carcinoma of Lung. (PMID:34833441)
- Clinical Characteristics of TZAP (ZBTB48) in Hepatocellular Carcinomas from Tissue, Cell Line, and TCGA. (PMID:36556980)
- Recruitment of the m[6]A/m6Am demethylase FTO to target RNAs by the telomeric zinc finger protein ZBTB48. (PMID:39300486)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | zbtb48 | ENSDARG00000039263 |
| mus_musculus | Zbtb48 | ENSMUSG00000028952 |
| rattus_norvegicus | Zbtb48 | ENSRNOG00000009595 |
Paralogs (36): ZNF302 (ENSG00000089335), ZNF184 (ENSG00000096654), CTCF (ENSG00000102974), ZNF574 (ENSG00000105732), ZBTB24 (ENSG00000112365), ZNF142 (ENSG00000115568), CTCFL (ENSG00000124092), ZNF473 (ENSG00000142528), ZNF827 (ENSG00000151612), ZNF689 (ENSG00000156853), ZNF208 (ENSG00000160321), ZNF91 (ENSG00000167232), ZNF526 (ENSG00000167625), ZNF764 (ENSG00000169951), ZNF747 (ENSG00000169955), ZNF282 (ENSG00000170265), ZNF160 (ENSG00000170949), ZNF497 (ENSG00000174586), ZBTB34 (ENSG00000177125), ZNF771 (ENSG00000179965), ZNF48 (ENSG00000180035), ZNF594 (ENSG00000180626), ZBTB37 (ENSG00000185278), ZFP92 (ENSG00000189420), ZNF107 (ENSG00000196247), ZNF729 (ENSG00000196350), ZNF569 (ENSG00000196437), ZNF420 (ENSG00000197050), ZNF785 (ENSG00000197162), ZNF665 (ENSG00000197497), ZNF181 (ENSG00000197841), ZNF347 (ENSG00000197937), ZNF84 (ENSG00000198040), ZNF845 (ENSG00000213799), ZNF99 (ENSG00000213973), ZNF688 (ENSG00000229809)
Protein
Protein identifiers
Zinc finger and BTB domain-containing protein 48 — P10074 (reviewed: P10074)
Alternative names: Krueppel-related zinc finger protein 3, Telomere zinc finger-associated protein, Telomere-binding protein and transcriptional activator ZBTB48, Zinc finger protein 855
All UniProt accessions (5): P10074, K7EM76, K7ENV2, Q5SY20, Q5SY21
UniProt curated annotations — full annotation on UniProt →
Function. Plays a critical role in transcriptional regulation and chromatin remodeling. Acts as a regulator of telomere length. Directly binds the telomeric double-stranded 5’-TTAGGG-3’ repeat. Preferentially binds to telomeres that have a low concentration of shelterin complex and acts as a regulator of telomere length by initiating telomere trimming, a process that prevents the accumulation of aberrantly long telomeres. Also acts as a transcription regulator that binds to promoter regions. Regulates expression of a small subset of genes, including MTFP1. Acts as a negative regulator of cell proliferation by specifically activating expression of ARF, a tumor suppressor isoform of CDKN2A. Acts as a transcription regulator of CIITA, the major factor regulating MHC class II gene expression. In addition, regulates cellular m6A/m6Am methylation on RNA by facilitating the recruitment of the RNA demethylase, FTO, to target mRNAs.
Subunit / interactions. Interacts with EP300.
Subcellular location. Nucleus. Chromosome. Telomere.
Tissue specificity. Detected in adrenal gland and neuroblastoma.
Domain organisation. The C2H2-type zinc fingers mediate binding to the telomeric double-stranded 5’-TTAGGG-3’ repeats. The last C2H2-type zinc finger is required for telomeric-binding. The two last C2H2-type zinc fingers are required for CIITA promoter III binding.
Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.
RefSeq proteins (3): NP_001265576, NP_001265577, NP_005332* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000210 | BTB/POZ_dom | Domain |
| IPR011333 | SKP1/BTB/POZ_sf | Homologous_superfamily |
| IPR013087 | Znf_C2H2_type | Domain |
| IPR036236 | Znf_C2H2_sf | Homologous_superfamily |
| IPR050758 | Znf_C2H2-type | Family |
Pfam: PF00096, PF00651
UniProt features (69 total): binding site 24, zinc finger region 11, helix 9, strand 6, sequence conflict 4, modified residue 3, turn 3, region of interest 2, cross-link 2, chain 1, domain 1, compositionally biased region 1, sequence variant 1, mutagenesis site 1
Structure
Experimental structures (PDB)
2 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 3B84 | X-RAY DIFFRACTION | 1.74 |
| 5YJ3 | X-RAY DIFFRACTION | 2.85 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P10074-F1 | 64.87 | 0.03 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Ligand- & substrate-binding residues (24): 293; 296; 309; 313; 321; 324; 337; 342; 352; 355; 368; 372 …
Post-translational modifications (5): 169, 171, 179, 143, 263
Mutagenesis-validated functional residues (1):
| Position | Phenotype |
|---|---|
| 596 | abolishes binding to the telomeric double-stranded 5’-ttaggg-3’ repeat. |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 99 (showing top):
GOBP_CHROMOSOME_ORGANIZATION, GOBP_TELOMERE_MAINTENANCE_VIA_TELOMERE_LENGTHENING, GOBP_TELOMERE_ORGANIZATION, WHITE_NEUROBLASTOMA_WITH_1P36.3_DELETION, EFC_Q6, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, KMCATNNWGGA_UNKNOWN, MODULE_123, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, FAELT_B_CLL_WITH_VH3_21_UP, GOCC_CHROMOSOMAL_REGION, SANSOM_APC_MYC_TARGETS, SANSOM_APC_TARGETS_REQUIRE_MYC, GOCC_CHROMOSOME_TELOMERIC_REGION
GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), telomere maintenance via telomere lengthening (GO:0010833), positive regulation of DNA-templated transcription (GO:0045893), regulation of RNA metabolic process (GO:0051252)
GO Molecular Function (11): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), double-stranded telomeric DNA binding (GO:0003691), DNA-binding transcription factor activity (GO:0003700), RNA binding (GO:0003723), zinc ion binding (GO:0008270), identical protein binding (GO:0042802), DNA binding (GO:0003677), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565), metal ion binding (GO:0046872)
GO Cellular Component (3): chromosome, telomeric region (GO:0000781), nucleus (GO:0005634), chromosome (GO:0005694)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| regulation of DNA-templated transcription | 3 |
| nucleic acid binding | 2 |
| transcription by RNA polymerase II | 1 |
| telomere maintenance | 1 |
| DNA-templated transcription | 1 |
| positive regulation of RNA biosynthetic process | 1 |
| RNA metabolic process | 1 |
| regulation of nucleobase-containing compound metabolic process | 1 |
| regulation of macromolecule metabolic process | 1 |
| transcription regulatory region nucleic acid binding | 1 |
| sequence-specific double-stranded DNA binding | 1 |
| RNA polymerase II transcription regulatory region sequence-specific DNA binding | 1 |
| cis-regulatory region sequence-specific DNA binding | 1 |
| double-stranded DNA binding | 1 |
| telomeric repeat DNA binding | 1 |
| transcription cis-regulatory region binding | 1 |
| transcription regulator activity | 1 |
| transition metal ion binding | 1 |
| protein binding | 1 |
| binding | 1 |
| DNA binding | 1 |
| cation binding | 1 |
| chromosomal region | 1 |
| intracellular membrane-bounded organelle | 1 |
| intracellular membraneless organelle | 1 |
Protein interactions and networks
STRING
1118 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ZBTB48 | TERF1 | P54274 | 636 |
| ZBTB48 | NOL9 | Q5SY16 | 626 |
| ZBTB48 | DCLRE1B | Q9H816 | 538 |
| ZBTB48 | TAS1R1 | Q7RTX1 | 502 |
| ZBTB48 | MYCL | P12524 | 498 |
| ZBTB48 | TINF2 | Q9BSI4 | 479 |
| ZBTB48 | NAIF1 | Q69YI7 | 471 |
| ZBTB48 | TERF2 | Q15554 | 455 |
| ZBTB48 | MYCN | P04198 | 455 |
| ZBTB48 | HMBOX1 | Q6NT76 | 446 |
| ZBTB48 | TERB2 | Q8NHR7 | 439 |
| ZBTB48 | SRBD1 | Q8N5C6 | 421 |
| ZBTB48 | NRAS | P01111 | 411 |
| ZBTB48 | NR2C2 | P49116 | 410 |
| ZBTB48 | NR2C1 | P13056 | 377 |
IntAct
107 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| INO80E | TFPT | psi-mi:“MI:0914”(association) | 0.790 |
| ZBTB8A | ZBTB48 | psi-mi:“MI:0915”(physical association) | 0.780 |
| ZBTB48 | ZBTB8A | psi-mi:“MI:0915”(physical association) | 0.780 |
| NME7 | ZBTB48 | psi-mi:“MI:0915”(physical association) | 0.720 |
| ZBTB48 | NME7 | psi-mi:“MI:0915”(physical association) | 0.720 |
| ZBTB48 | ZBTB48 | psi-mi:“MI:0915”(physical association) | 0.670 |
| ZBTB48 | TRIM41 | psi-mi:“MI:0915”(physical association) | 0.670 |
| ZBTB48 | DVL3 | psi-mi:“MI:0915”(physical association) | 0.670 |
| DVL3 | ZBTB48 | psi-mi:“MI:0915”(physical association) | 0.670 |
| ZBTB48 | KRTAP10-5 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB48 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| KRTAP10-5 | ZBTB48 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB48 | KRTAP1-1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB48 | CEP70 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB48 | THAP1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB48 | TSPYL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB48 | L3MBTL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB48 | SPANXN2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB48 | ZNF837 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB48 | ZBTB9 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (213): ZBTB48 (Two-hybrid), NME7 (Two-hybrid), GPATCH2L (Two-hybrid), KRTAP10-5 (Two-hybrid), ZBTB8A (Two-hybrid), C7orf34 (Two-hybrid), ZBTB48 (Two-hybrid), ZBTB48 (Synthetic Growth Defect), ZBTB48 (Two-hybrid), TRIM41 (Two-hybrid), ZBTB48 (Affinity Capture-MS), ZBTB48 (Affinity Capture-MS), ZBTB48 (Affinity Capture-MS), ZBTB48 (Affinity Capture-MS), ZBTB48 (Affinity Capture-MS)
ESM2 similar proteins: A1L1J6, A2A5K6, A2APF3, D3ZUU2, E9Q8T2, G3V893, G5E8B9, O43167, O70237, O95625, P10074, P22227, P52739, P57071, P98169, Q05516, Q13105, Q1H9T6, Q3B725, Q3B7N9, Q3U288, Q3UH06, Q4VBD9, Q5DU09, Q5EAC5, Q5R633, Q5VTD9, Q60821, Q6DDV0, Q6GL52, Q6NS86, Q6YND2, Q6ZSB9, Q7TS63, Q80X44, Q8BKX7, Q8BXX2, Q8C8V1, Q8CCE9, Q8N1W2
Diamond homologs: A0A0A6YY25, B2RXH4, E0CZ16, E1B932, E7F6F9, F1LZ52, F1LZF0, F1MBP6, O88282, O93567, O95198, P10074, P17789, P42282, P42283, P42284, Q01295, Q1H9T6, Q24174, Q24206, Q3B7M1, Q52KG4, Q53G59, Q53HC5, Q5R633, Q5REP9, Q5U374, Q66HD2, Q6NRH0, Q7KQZ4, Q7KRI2, Q867Z4, Q86B87, Q8BGY4, Q8BZM0, Q8CA72, Q8IN81, Q8JZP3, Q8K0L9, Q8N143
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 56 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| regulation of cell cycle | 6 | 9.5× | 8e-03 |
Disease & clinical
Cancer significance
From intOGen — cancer-driver classification: activating (oncogene-like) across 1 cancer types — ANGS.
Clinical variants and AI predictions
ClinVar
88 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 75 |
| Likely benign | 5 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1928 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 1:6581063:G:GT | donor_gain | 1.0000 |
| 1:6585913:T:A | acceptor_gain | 1.0000 |
| 1:6585913:TGGCA:T | acceptor_loss | 1.0000 |
| 1:6585914:GGCA:G | acceptor_loss | 1.0000 |
| 1:6585915:GCA:G | acceptor_loss | 1.0000 |
| 1:6585916:CAGGA:C | acceptor_loss | 1.0000 |
| 1:6586772:G:T | donor_gain | 1.0000 |
| 1:6587203:A:AG | acceptor_gain | 1.0000 |
| 1:6587203:AGT:A | acceptor_gain | 1.0000 |
| 1:6587204:G:GT | acceptor_gain | 1.0000 |
| 1:6587204:GT:G | acceptor_gain | 1.0000 |
| 1:6587204:GTG:G | acceptor_gain | 1.0000 |
| 1:6587204:GTGT:G | acceptor_gain | 1.0000 |
| 1:6587204:GTGTT:G | acceptor_gain | 1.0000 |
| 1:6587287:ATGCA:A | donor_gain | 1.0000 |
| 1:6587288:TGCA:T | donor_gain | 1.0000 |
| 1:6587289:GCA:G | donor_gain | 1.0000 |
| 1:6587289:GCAG:G | donor_gain | 1.0000 |
| 1:6587290:CA:C | donor_gain | 1.0000 |
| 1:6587292:G:GG | donor_gain | 1.0000 |
| 1:6587292:GTAA:G | donor_loss | 1.0000 |
| 1:6587293:T:G | donor_loss | 1.0000 |
| 1:6587464:T:A | acceptor_gain | 1.0000 |
| 1:6587476:A:AG | acceptor_gain | 1.0000 |
| 1:6587477:G:GA | acceptor_gain | 1.0000 |
| 1:6587513:A:AG | acceptor_gain | 1.0000 |
| 1:6587514:G:GG | acceptor_gain | 1.0000 |
| 1:6587514:GA:G | acceptor_gain | 1.0000 |
| 1:6587629:ACAGG:A | donor_loss | 1.0000 |
| 1:6587630:CAGG:C | donor_loss | 1.0000 |
AlphaMissense
4546 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 1:6587565:T:C | C438R | 1.000 |
| 1:6588100:T:C | F474L | 1.000 |
| 1:6588102:C:A | F474L | 1.000 |
| 1:6588102:C:G | F474L | 1.000 |
| 1:6588184:T:C | F502L | 1.000 |
| 1:6588186:C:A | F502L | 1.000 |
| 1:6588186:C:G | F502L | 1.000 |
| 1:6588349:T:C | F530L | 1.000 |
| 1:6588351:C:A | F530L | 1.000 |
| 1:6588351:C:G | F530L | 1.000 |
| 1:6588415:T:C | C552R | 1.000 |
| 1:6588812:T:C | C580R | 1.000 |
| 1:6588833:T:C | F587L | 1.000 |
| 1:6588834:T:C | F587S | 1.000 |
| 1:6588835:T:A | F587L | 1.000 |
| 1:6588835:T:G | F587L | 1.000 |
| 1:6588923:T:C | L593P | 1.000 |
| 1:6582244:T:C | C293R | 0.999 |
| 1:6582253:T:C | C296R | 0.999 |
| 1:6582265:T:C | F300L | 0.999 |
| 1:6582266:T:C | F300S | 0.999 |
| 1:6582267:C:A | F300L | 0.999 |
| 1:6582267:C:G | F300L | 0.999 |
| 1:6582284:T:C | L306P | 0.999 |
| 1:6582292:C:G | H309D | 0.999 |
| 1:6585925:T:A | H313Q | 0.999 |
| 1:6585925:T:G | H313Q | 0.999 |
| 1:6585947:T:C | C321R | 0.999 |
| 1:6585956:T:C | C324R | 0.999 |
| 1:6585987:T:C | L334P | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000024691 (1:6579158 G>A), RS1000244169 (1:6588420 G>C), RS1001155888 (1:6584472 T>C), RS1001371752 (1:6583944 T>C), RS1001434005 (1:6584548 C>T), RS1001540873 (1:6586315 T>A), RS1001885224 (1:6584213 C>G,T), RS1001886888 (1:6586009 T>A,C), RS1001914386 (1:6580917 G>A), RS1003590264 (1:6582418 T>C), RS1003827265 (1:6585514 C>A), RS1003896582 (1:6588826 C>A,T), RS1004117369 (1:6585295 T>G), RS1004427144 (1:6585265 G>A), RS1004781637 (1:6583927 G>A)
Disease associations
OMIM: gene MIM:165270 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST010989_23 | Body size at age 10 | 2.000000e-13 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0009819 | comparative body size at age 10, self-reported |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL5069366 (SINGLE PROTEIN)
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
20 total (human), top 20 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| FR900359 | decreases phosphorylation | 1 |
| TAK-243 | increases sumoylation | 1 |
| triphenyl phosphate | affects expression | 1 |
| perfluorooctanoic acid | decreases expression | 1 |
| M-VAC protocol | decreases response to substance | 1 |
| abrine | increases expression | 1 |
| 4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid | increases expression | 1 |
| Temozolomide | increases expression | 1 |
| Sunitinib | increases expression | 1 |
| Air Pollutants | affects expression, increases abundance | 1 |
| Ethanol | affects cotreatment, increases abundance, increases expression | 1 |
| Caffeine | decreases phosphorylation | 1 |
| Dichlorodiphenyl Dichloroethylene | decreases expression | 1 |
| Gasoline | affects cotreatment, increases abundance, increases expression | 1 |
| Methyl Methanesulfonate | increases expression | 1 |
| Ozone | affects expression, increases abundance | 1 |
| Phthalic Acids | affects methylation | 1 |
| Polycyclic Aromatic Hydrocarbons | affects cotreatment, increases abundance, increases expression | 1 |
| Smoke | decreases expression | 1 |
| Particulate Matter | affects cotreatment, increases abundance, increases expression | 1 |
ChEMBL screening assays
3 unique, capped per target: 3 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL5059499 | Binding | Proteomics fold change data (SUDHL4 cells, 1h) | Data for DCP probe CCT369260 |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_XV92 | HEK293 eGFP-ZBTB48 | Transformed cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.